Bio-Thera Solutions Ltd
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metast… Read more
Bio-Thera Solutions Ltd (688177) - Total Assets
Latest total assets as of June 2025: CN¥2.25 Billion CNY
Based on the latest financial reports, Bio-Thera Solutions Ltd (688177) holds total assets worth CN¥2.25 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bio-Thera Solutions Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Bio-Thera Solutions Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bio-Thera Solutions Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Bio-Thera Solutions Ltd's total assets of CN¥2.25 Billion consist of 40.3% current assets and 59.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 13.1% |
| Accounts Receivable | CN¥104.15 Million | 4.7% |
| Inventory | CN¥253.10 Million | 11.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥224.10 Million | 10.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Bio-Thera Solutions Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bio-Thera Solutions Ltd's current assets represent 40.3% of total assets in 2024, a decrease from 46.9% in 2016.
- Cash Position: Cash and equivalents constituted 13.1% of total assets in 2024, up from 1.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 11.5% of total assets.
Bio-Thera Solutions Ltd Competitors by Total Assets
Key competitors of Bio-Thera Solutions Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Bio-Thera Solutions Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Bio-Thera Solutions Ltd generates 0.34x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Bio-Thera Solutions Ltd is currently not profitable relative to its asset base.
Bio-Thera Solutions Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.79 | 1.05 | 6.92 |
| Quick Ratio | 0.56 | 0.82 | 6.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-244.58 Million | CN¥ 45.08 Million | CN¥ 1.25 Billion |
Bio-Thera Solutions Ltd - Advanced Valuation Insights
This section examines the relationship between Bio-Thera Solutions Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.27 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -3.6% |
| Total Assets | CN¥2.21 Billion |
| Market Capitalization | $364.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bio-Thera Solutions Ltd's assets below their book value (0.17 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Bio-Thera Solutions Ltd's assets decreased by 3.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Bio-Thera Solutions Ltd (2016–2024)
The table below shows the annual total assets of Bio-Thera Solutions Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.21 Billion | -3.57% |
| 2023-12-31 | CN¥2.29 Billion | +4.93% |
| 2022-12-31 | CN¥2.18 Billion | -16.73% |
| 2021-12-31 | CN¥2.62 Billion | +9.39% |
| 2020-12-31 | CN¥2.39 Billion | +135.93% |
| 2019-12-31 | CN¥1.01 Billion | -0.63% |
| 2018-12-31 | CN¥1.02 Billion | +64.92% |
| 2017-12-31 | CN¥618.94 Million | -12.61% |
| 2016-12-31 | CN¥708.29 Million | -- |